Home > Product > APIs > Endothelin-1 (human, bovine, dog, mouse, porcine, rat) Acetate

APIs

Endothelin-1 (human, bovine, dog, mouse, porcine, rat) Acetate

Price Inquiry
CAT#
10-101-82
Synonyms/Alias
ET-1; Endothelin-1; Endothelin1; Endothelin 1
CAS No.
117399-94-7 (net)
Sequence
H-Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-OH acetate salt (Disulfide bonds between Cys1 and Cys15/Cys3 and Cys11)
M.W/Mr.
2491.94
Molecular Formula
C109H159N25O32S5
Source
Synthetic
Long-term Storage Conditions
−20°C
Application
Endothelin-1 is a highly potent vasoconstrictor which is synthesized in the vascular endothelium and many other tissues.
Description
Endothelin-1, a 21-amino acid peptide from vascular endothelial cells of different mammalian species, is one of the most potent vasoconstrictors. ET-1 exerts a wide variety of effects on both vascular and non-vascular (e.g. heart, lung, brain) tissues. Also ET-1 plays a central role in lung fibrosis.
Areas of Interest
Cardiovascular disease
  • Background
  • Related Products
  • References

Endothelin-1 (ET-1) is a vasoconstrictor secreted by endothelial cells, which acts as the natural counterpart of the vasodilator nitric oxide (NO). ET-1 contributes to vascular tone and regulates cell proliferation through activation of ETA and ETB receptors. Physical factors such as shear stress, or stimuli including thrombin, epinephrine, angiotensin II, growth factors, cytokines and free radicals enhance secretion of ET-1. By contrast, mediators like nitric oxide (NO), cyclic GMP, atrial natriuretic peptide, and prostacyclin reduce the release of endogenous ET-1. Thus, under normal conditions, the effects of the ET-1 are carefully regulated through inhibition or stimulation of ET-1 release from endothelium.

CAS: 113-79-1
Sequence: Cys-Tyr-Phe-Gln-Asn-Cys-Pro-Arg-Gly-NH2 (Disulfide bond 1-6)
M.W: 1084.21
Molecular Formula: C46H65N15O12S2
CAS: 124584-08-3 (net)
Sequence: H-Ser-Pro-Lys-Met-Val-Gln-Gly-Ser-Gly-Cys-Phe-Gly-Arg-Lys-Met-Asp-Arg-Ile-Ser-Ser-Ser-Ser-Gly-Leu-Gly-Cys-Lys-Val-Leu-Arg-Arg-His-OH Acetate salt (Disulfide bond)
M.W: 3464.09
Molecular Formula: C143H244N50O42S4
CAS: 69-25-0
Sequence: Pyr-Pro-Ser-Lys-Asp-Ala-Phe-Ile-Gly-Leu-Met-NH2
M.W: 1188.4
Molecular Formula: C54H85N13O15S
CAS: 138068-37-8 (net)
Sequence: H-Leu-Thr-Tyr-Thr-Asp-Cys-Thr-Glu-Ser-Gly-Gln-Asn-Leu-Cys-Leu-Cys-Glu-Gly-Ser-Asn-Val-Cys-Gly-Gln-Gly-Asn-Lys-Cys-Ile-Leu-Gly-Ser-Asp-Gly-Glu-Lys-Asn-Gln-Cys-Val-Thr-Gly-Glu-Gly-Thr-Pro-Lys-Pro-Gln-Ser-His-Asn-Asp-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-L
M.W: 6979.52
Molecular Formula: C287H440N80O111S6
CAS: 355151-12-1
Sequence: Ac-D-Tyr-D-Pro-D-Hyp-Gly-D-Ala-Gly-NH2
M.W: 617.65
Molecular Formula: C28H39N7O9

Over two decades of research have demonstrated that the peptide hormone endothelin-1 (ET-1) plays multiple, complex roles in cardiovascular, neural, pulmonary, reproductive, and renal physiology. Differential and tissue-specific production of ET-1 must be tightly regulated in order to preserve these biologically diverse actions. The primary mechanism thought to control ET-1 bioavailability is the rate of transcription from the ET-1 gene (edn1). Studies conducted on a variety of cell types have identified key transcription factors that govern edn1 expression.

Stow, L. R., Jacobs, M. E., Wingo, C. S., & Cain, B. D. (2011). Endothelin-1 gene regulation. The FASEB Journal, 25(1), 16-28.

Moderate or strong immunostaining was observed for ET-1 in 25.4%, for ET(A)R in 43.7%, and for ET(B)R in 22.2% of breast carcinomas. Of all cases, 44.7% showed significant expression of VEGF. MVD varied between different tumor specimens (range, 0-80; median, 17). We observed a statistically significant correlation between MVD and ET expression status with higher MVD in ET-positive tumors. Moreover, expression of VEGF was found more frequently in tumors with overexpression of the ET axis (each P < 0.001). Staining of VEGF was correlated positively with MVD CONCLUSIONS: These results indicate that increased ET-1, ET(A)R, and ET(B)R expression is associated with increased VEGF expression and higher vascularity of breast carcinomas and, thus, could be involved in the regulation of angiogenesis in breast cancer. Our findings provide evidence that the expression pattern of the ET-axis and in particular of ET(A)R may have clinical relevance in future antiangiogenic targeted therapies for breast cancer.

Wülfing, P., Kersting, C., Tio, J., Fischer, R. J., Wülfing, C., Poremba, C., ... & Kiesel, L. (2004). Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer. Clinical cancer research, 10(7), 2393-2400.

Online Inquiry

Name (First Last) *
Email *
Phone *
Service & Products of Interest *
Quantities
Purity
Services Required and Project Description
Verification code *Please enter the code "peptides"
Home | Site Map | Contact Us | Resources
Copyright © 2008 - Creative Peptides. All rights reserved.